Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies beyond Dopamine Receptor Antagonism

CNS Drugs

Volumn 29, Issue 9, 2015, Pages 773-799

  De Bartolomeis, Andrea ^a   Tomasetti, Carmine ^a   Iasevoli, Felice ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 4 PHENYL 1 [(3 PHENYL 3 CYCLOHEXEN 1 YL)METHYL]PYRIDINE; APLINDORE; ARIPIPRAZOLE; AUTORECEPTOR; BIFEPRUNOX; BREXPIPRAZOLE; CARIPRAZINE; DOPAMINE 2 RECEPTOR; DOPAMINE AUTORECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; MITOGEN ACTIVATED PROTEIN KINASE; NEUROLEPTIC AGENT; ORDOPIDINE; PARTIAL AGONIST; PRIDOPIDINE; SEROTONIN RECEPTOR; TALIPEXOLE; TRANSCRIPTOME;

ARTICLE; CELL PROTECTION; DOPAMINE RECEPTOR BLOCKING; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; HUMAN; IN VIVO STUDY; INTRACELLULAR SIGNALING; LONG TERM CARE; MULTICENTER STUDY (TOPIC); NERVE CELL PLASTICITY; NERVE FIBER GROWTH; NEUROBIOLOGY; NEUROIMAGING; NEUROMODULATION; NEUROPATHOLOGY; NONHUMAN; PARTIAL AGONISM; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BINDING; RECEPTOR INTRINSIC ACTIVITY; SCHIZOPHRENIA; TRANSLATIONAL RESEARCH; ANIMAL; MENTAL DISORDERS;

ANIMALS; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; HUMANS; MENTAL DISORDERS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84943814001     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-015-0278-3     Document Type: Article

References (212)

1. de Bartolomeis A, Buonaguro EF, Iasevoli F. Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins. Psychopharmacology (Berl). 2013;225(1):1-19.
2. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophr Bull. 2009;35(3):549-62.
3. de Bartolomeis A, Latte G, Tomasetti C, et al. Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches. Mol Neurobiol. 2014;49(1):484-511.
4. Hall J, Trent S, Thomas KL, et al. Genetic risk for schizophrenia: convergence on synaptic pathways involved in plasticity. Biol Psychiatry. 2015;77(1):52-8.
5. Wen Z, Nguyen HN, Guo Z, et al. Synaptic dysregulation in a human iPS cell model of mental disorders. Nature. 2014;515(7527):414-8.
6. van den Heuvel MP, Fornito A. Brain networks in schizophrenia. Neuropsychol Rev. 2014;24(1):32-48.
7. Usun Y, Eybrard S, Meyer F, et al. Ketamine increases striatal dopamine release and hyperlocomotion in adult rats after postnatal functional blockade of the prefrontal cortex. Behav Brain Res. 2013;256:229-37.
8. Breier A, Su TP, Saunders R, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA. 1997;94(6):2569-74.
9. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1081-90.
10. FDA U. Inventor drug approval package, Abilify (aripiprazole) tablets. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails2002.
11. FDA U. Inventor drug approval package, Abilify (aripiprazole) solution. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails2004.
12. Kim JR, Seo HB, Cho JY, et al. Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients. Br J Clin Pharmacol. 2008;66(6):802-10.
13. Grunder G, Fellows C, Janouschek H, et al. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am J Psychiatry. 2008;165(8):988-95.
14. Yokoi F, Grunder G, Biziere K, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology. 2002;27(2):248-59.
15. Kirschbaum KM, Muller MJ, Malevani J, et al. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry. 2008;9(3):212-8.
16. FDA U. Drug approval package, Abilify (aripiprazole) intramuscular injectable solution. 2006. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.
17. FDA U. Drug approval package, Abilify Maintena (aripiprazole), extended-release intramuscular injectable solution. 2013. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.
18. Raoufinia A, Baker RA, Eramo A, et al. Initiation of aripiprazole once-monthly in patients with schizophrenia. Curr Med Res Opin. 2015;31(3):583-92.
19. Kubo M, Koue T, Inaba A, et al. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE. Drug Metab Pharmacokinet. 2005;20(1):55-64.
20. Kubo M, Koue T, Maune H, et al. Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab Pharmacokinet. 2007;22(5):358-66.
21. Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002;54(10):1271-94.
22. Azuma J, Hasunuma T, Kubo M, et al. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. Eur J Clin Pharmacol. 2012;68(1):29-37.
23. de Bartolomeis A, Perugi G. Combination of aripiprazole with mood stabilizers for the treatment of bipolar disorder: from acute mania to long-term maintenance. Expert Opin Pharmacother. 2012;13(14):2027-36.
24. Citrome L, Macher JP, Salazar DE, et al. Pharmacokinetics of aripiprazole and concomitant carbamazepine. J Clin Psychopharmacol. 2007;27(3):279-83.
25. Mallikaarjun S, Kane JM, Bricmont P, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res. 2013;150(1):281-8.
26. Molden E, Lunde H, Lunder N, et al. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit. 2006;28(6):744-9.
27. Koch I, Weil R, Wolbold R, et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos. 2002;30(10):1108-14.
28. Kenakin T. Agonist-specific receptor conformations. Trends Pharmacol Sci. 1997;18(11):416-7.
29. Kenakin T, Williams M. Defining and characterizing drug/compound function. Biochem Pharmacol. 2014;87(1):40-63.
30. Urban JD, Clarke WP, von Zastrow M, et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther. 2007;320(1):1-13.
31. Zhu J, Taniguchi T, Takauji R, et al. Inverse agonism and neutral antagonism at a constitutively active alpha-1a adrenoceptor. Br J Pharmacol. 2000;131(3):546-52.
32. Kenakin T. Functional selectivity: theoretical consideration and future direction. In: Neve KA, editor. Functional selectivity of G protein-coupled receptor ligands. New York: Humana Press; 2009. p. 9-24.
33. Mailman R, Wang YM, Kant A, et al. Functional selectivity at dopamine receptors. In: Neve KA, editor. Functional selectivity of G protein-coupled receptor ligands. New York: Humana Press; 2009. p. 177-209.
34. Mailman RB, Murthy V. Ligand functional selectivity advances our understanding of drug mechanisms and drug discovery. Neuropsychopharmacology. 2010;35(1):345-6.
35. Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des. 2010;16(5):488-501.
36. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28(8):1400-11.
37. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302(1):381-9.
38. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63(9):763-71.
39. Tadori Y, Forbes RA, McQuade RD, et al. Functional potencies of dopamine agonists and antagonists at human dopamine D(2) and D(3) receptors. Eur J Pharmacol. 2011;666(1-3):43-52.
40. Tadori Y, Forbes RA, McQuade RD, et al. In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. Eur J Pharmacol. 2011;668(3):355-65.
41. Bruins Slot LA, Palmier C, Tardif S, et al. Action of novel antipsychotics at human dopamine D3 receptors coupled to G protein and ERK1/2 activation. Neuropharmacology. 2007;53(2):232-41.
42. Urban JD, Vargas GA, von Zastrow M, et al. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology. 2007;32(1):67-77.
43. Hamamura T, Harada T. Unique pharmacological profile of aripiprazole as the phasic component buster. Psychopharmacology (Berl). 2007;191(3):741-3.
44. Ma GF, Raivio N, Sabria J, et al. Agonist and antagonist effects of aripiprazole on D(2)-like receptors controlling rat brain dopamine synthesis depend on the dopaminergic tone. Int J Neuropsychopharmacol. 2015;18(4).
45. Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 1999;20(6):612-27.
46. Mailman RB. GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci. 2007;28(8):390-6.
47. Shan J, Khelashvili G, Mondal S, et al. Ligand-dependent conformations and dynamics of the serotonin 5-HT(2A) receptor determine its activation and membrane-driven oligomerization properties. PLoS Comput Biol. 2012;8(4):e1002473.
48. Kofuku Y, Ueda T, Okude J, et al. Efficacy of the beta(2)-adrenergic receptor is determined by conformational equilibrium in the transmembrane region. Nat Commun. 2012;3:1045.
49. Kling RC, Tschammer N, Lanig H, et al. Active-state model of a dopamine d2 receptor - galphai complex stabilized by aripiprazole-type partial agonists. PLoS One. 2014;9(6):e100069.
50. Heusler P, Newman-Tancredi A, Castro-Fernandez A, et al. Differential agonist and inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels. Neuropharmacology. 2007;52(4):1106-13.
51. Kikuchi T, Tottori K, Uwahodo Y, et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinon e (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther. 1995;274(1):329-36.
52. Lahti AC, Weiler MA, Corey PK, et al. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia. Biol Psychiatry. 1998;43(1):2-11.
53. Olbrich R, Schanz H. An evaluation of the partial dopamine agonist terguride regarding positive symptoms reduction in schizophrenics. J Neural Transm Gen Sect. 1991;84(3):233-6.
54. Natesan S, Reckless GE, Barlow KB, et al. Partial agonists in schizophrenia - why some work and others do not: insights from preclinical animal models. Int J Neuropsychopharmacol. 2011;14(9):1165-78.
55. Newman-Tancredi A, Assie MB, Leduc N, et al. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol. 2005;8(3):341-56.
56. Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002;441(3):137-40.
57. Stark AD, Jordan S, Allers KA, et al. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl). 2007;190(3):373-82.
58. Millan MJ. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J Pharmacol Exp Ther. 2000;295(3):853-61.
59. Nagai T, Murai R, Matsui K, et al. Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology (Berl). 2009;202(1-3):315-28.
60. Bruins Slot LA, Kleven MS, Newman-Tancredi A. Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat. Neuropharmacology. 2005;49(7):996-1006.
61. Snigdha S, Neill JC. Improvement of phencyclidine-induced social behaviour deficits in rats: involvement of 5-HT1A receptors. Behav Brain Res. 2008;191(1):26-31.
62. Li Z, Ichikawa J, Dai J, et al. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol. 2004;493(1-3):75-83.
63. Zocchi A, Fabbri D, Heidbreder CA. Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex. Neurosci Lett. 2005;387(3):157-61.
64. Assie MB, Ravailhe V, Faucillon V, et al. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther. 2005;315(1):265-72.
65. Bortolozzi A, Diaz-Mataix L, Toth M, et al. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology (Berl). 2007;191(3):745-58.
66. Tanahashi S, Yamamura S, Nakagawa M, et al. Dopamine D2 and serotonin 5-HT1A receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission. Neuropharmacology. 2012;62(2):765-74.
67. Carli M, Calcagno E, Mainolfi P, et al. Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex. Psychopharmacology (Berl). 2011;214(3):639-52.
68. Carli M, Invernizzi RW. Serotoninergic and dopaminergic modulation of cortico-striatal circuit in executive and attention deficits induced by nMDA receptor hypofunction in the 5-choice serial reaction time task. Front Neural Circuits. 2014;8:58.
69. Bortolozzi A, Amargos-Bosch M, Adell A, et al. In vivo modulation of 5-hydroxytryptamine release in mouse prefrontal cortex by local 5-HT(2A) receptors: effect of antipsychotic drugs. Eur J Neurosci. 2003;18(5):1235-46.
70. Zhang JY, Kowal DM, Nawoschik SP, et al. Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol. 2006;71(4):521-9.
71. Kohnomi S, Suemaru K, Kawasaki H, et al. Effect of aripiprazole on 5-HT2 receptor-mediated wet-dog shake responses and disruption of prepulse inhibition in rats. J Pharmacol Sci. 2008;106(4):645-50.
72. Nguyen CT, Rosen JA, Bota RG. Aripiprazole partial agonism at 5-HT2C: a comparison of weight gain associated with aripiprazole adjunctive to antidepressants with high versus low serotonergic activities. Prim Care Companion CNS Disord. 2012;14(5).
73. de Bartolomeis A, Avvisati L, Iasevoli F, et al. Intracellular pathways of antipsychotic combined therapies: implication for psychiatric disorders treatment. Eur J Pharmacol. 2013;718(1-3):502-23.
74. Farde L, Nordstrom AL, Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992;49(7):538-44.
75. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157(4):514-20.
76. Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci. 2000;25(2):161-6.
77. Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry. 2000;57(6):553-9.
78. Mamo D, Graff A, Mizrahi R, et al. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry. 2007;164(9):1411-7.
79. Kegeles LS, Slifstein M, Frankle WG, et al. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology. 2008;33(13):3111-25.
80. Grunder G, Landvogt C, Vernaleken I, et al. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology. 2006;31(5):1027-35.
81. Tomasetti C, Dell'Aversano C, Iasevoli F, et al. Homer splice variants modulation within cortico-subcortical regions by dopamine D2 antagonists, a partial agonist, and an indirect agonist: implication for glutamatergic postsynaptic density in antipsychotics action. Neuroscience. 2007;150(1):144-58.
82. Takahata K, Ito H, Takano H, et al. Striatal and extrastriatal dopamine D(2) receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [(1)(1)C]raclopride and [(1)(1)C]FLB457. Psychopharmacology (Berl). 2012;222(1):165-72.
83. Ito H, Takano H, Arakawa R, et al. Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[beta-11C]DOPA. PLoS One. 2012;7(9):e46488.
84. Der-Ghazarian T, Charntikov S, Varela FA, et al. Effects of repeated and acute aripiprazole or haloperidol treatment on dopamine synthesis in the dorsal striatum of young rats: comparison to adult rats. J Neural Transm. 2010;117(5):573-83.
85. Han M, Huang XF, Deng C. Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects. Int J Neuropsychopharmacol. 2009;12(7):941-52.
86. Inoue A, Seto M, Sugita S, et al. Differential effects on D2 dopamine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat pituitary. Brain Res Mol Brain Res. 1998;55(2):285-92.
87. De Berardis D, Fornaro M, Serroni N, et al. Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole. Recent Pat Endocr Metab Immune Drug Discov. 2014;8(1):30-7.
88. Han M, Huang XF, du Bois TM, et al. The effects of antipsychotic drugs administration on 5-HT1A receptor expression in the limbic system of the rat brain. Neuroscience. 2009;164(4):1754-63.
89. Han M, Deng C, Burne TH, et al. Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression. Psychoneuroendocrinology. 2008;33(5):569-80.
90. Han M, Newell K, Zavitsanou K, et al. Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain. J Neurosci Res. 2008;86(2):457-64.
91. Peselmann N, Schmitt A, Gebicke-Haerter PJ, et al. Aripiprazole differentially regulates the expression of Gad67 and gamma-aminobutyric acid transporters in rat brain. Eur Arch Psychiatry Clin Neurosci. 2013;263(4):285-97.
92. Segnitz N, Ferbert T, Schmitt A, et al. Effects of chronic oral treatment with aripiprazole on the expression of nMDA receptor subunits and binding sites in rat brain. Psychopharmacology (Berl). 2011;217(1):127-42.
93. Segnitz N, Schmitt A, Gebicke-Harter PJ, et al. Differential expression of glutamate transporter genes after chronic oral treatment with aripiprazole in rats. Neurochem Int. 2009;55(7):619-28.
94. Cheng MC, Liao DL, Hsiung CA, et al. Chronic treatment with aripiprazole induces differential gene expression in the rat frontal cortex. Int J Neuropsychopharmacol. 2008;11(2):207-16.
95. Lyford GL, Yamagata K, Kaufmann WE, et al. Arc, a growth factor and activity-regulated gene, encodes a novel cytoskeleton-associated protein that is enriched in neuronal dendrites. Neuron. 1995;14(2):433-45.
96. Waters S, Ponten H, Edling M, et al. The dopaminergic stabilizers pridopidine and ordopidine enhance cortico-striatal Arc gene expression. J Neural Transm. 2014;121(11):1337-47.
97. de Bartolomeis A, Iasevoli F. The Homer family and the signal transduction system at glutamatergic postsynaptic density: potential role in behavior and pharmacotherapy. Psychopharmacol Bull. 2003;37(3):51-83.
98. Iasevoli F, Tomasetti C, de Bartolomeis A. Scaffolding proteins of the post-synaptic density contribute to synaptic plasticity by regulating receptor localization and distribution: relevance for neuropsychiatric diseases. Neurochem Res. 2013;38(1):1-22.
99. Iasevoli F, Tomasetti C, Marmo F, et al. Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole. Psychopharmacology (Berl). 2010;212(3):329-44.
100. Iasevoli F, Fiore G, Cicale M, et al. Haloperidol induces higher Homer1a expression than risperidone, olanzapine and sulpiride in striatal sub-regions. Psychiatry Res. 2010;177(1-2):255-60.
101. Iasevoli F, Ambesi-Impiombato A, Fiore G, et al. Pattern of acute induction of Homer1a gene is preserved after chronic treatment with first- and second-generation antipsychotics: effect of short-term drug discontinuation and comparison with Homer1a-interacting genes. J Psychopharmacol. 2011;25(7):875-87.
102. Tomasetti C, Dell'Aversano C, Iasevoli F, et al. The acute and chronic effects of combined antipsychotic-mood stabilizing treatment on the expression of cortical and striatal postsynaptic density genes. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):184-97.
103. de Bartolomeis A, Marmo F, Buonaguro EF, et al. Imaging brain gene expression profiles by antipsychotics: region-specific action of amisulpride on postsynaptic density transcripts compared to haloperidol. Eur Neuropsychopharmacol. 2013;23(11):1516-29.
104. Iasevoli F, Tomasetti C, Ambesi-Impiombato A, et al. Dopamine receptor subtypes contribution to Homer1a induction: insights into antipsychotic molecular action. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(5):813-21.
105. Iasevoli F, Polese D, Ambesi-Impiombato A, et al. Ketamine-related expression of glutamatergic postsynaptic density genes: possible implications in psychosis. Neurosci Lett. 2007;416(1):1-5.
106. de Bartolomeis A, Sarappa C, Buonaguro EF, et al. Different effects of the nMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: role of Homer signaling, and implications for novel antipsychotic and pro-cognitive targets in psychosis. Prog Neuropsychopharmacol Biol Psychiatry. 2013;46:1-12.
107. Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci. 2008;9(6):437-52.
108. Stefansson H, Ophoff RA, Steinberg S, et al. Common variants conferring risk of schizophrenia. Nature. 2009;460(7256):744-7.
109. Yin DM, Chen YJ, Lu YS, et al. Reversal of behavioral deficits and synaptic dysfunction in mice overexpressing neuregulin 1. Neuron. 2013;78(4):644-57.
110. Kwon OB, Paredes D, Gonzalez CM, et al. Neuregulin-1 regulates LTP at CA1 hippocampal synapses through activation of dopamine D4 receptors. Proc Natl Acad Sci USA. 2008;105(40):15587-92.
111. Deng C, Pan B, Hu CH, et al. Differential effects of short- and long-term antipsychotic treatment on the expression of neuregulin-1 and ErbB4 receptors in the rat brain. Psychiatry Res. 2015;225(3):347-54.
112. Ram R, Bromet EJ, Eaton WW, et al. The natural course of schizophrenia: a review of first-admission studies. Schizophr Bull. 1992;18(2):185-207.
113. Menezes NM, Arenovich T, Zipursky RB. A systematic review of longitudinal outcome studies of first-episode psychosis. Psychol Med. 2006;36(10):1349-62.
114. Suzuki T, Uchida H, Takeuchi H, et al. A review on schizophrenia and relapse-a quest for user-friendly psychopharmacotherapy. Hum Psychopharmacol. 2014;29(5):414-26.
115. Johnson DA. Historical perspective on antipsychotic long-acting injections. Br J Psychiatry Suppl. 2009;52:S7-12.
116. Kirson NY, Weiden PJ, Yermakov S, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry. 2013;74(6):568-75.
117. Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40(1):192-213.
118. Rauch AS, Fleischhacker WW. Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective. CNS Drugs. 2013;27(8):637-52.
119. Bressan RA, Jones HM, Ell PJ, et al. Dopamine D(2) receptor blockade in schizophrenia. Am J Psychiatry. 2001;158(6):971-2.
120. Turrone P, Remington G, Kapur S, et al. Differential effects of within-day continuous vs. transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats. Neuropsychopharmacology. 2003;28(8):1433-9.
121. Turrone P, Remington G, Kapur S, et al. Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats. Biol Psychiatry. 2005;57(4):406-11.
122. Samaha AN, Reckless GE, Seeman P, et al. Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biol Psychiatry. 2008;64(2):145-52.
123. Uchida H, Suzuki T. Dose and dosing frequency of long-acting injectable antipsychotics: a systematic review of PET and SPECT data and clinical implications. J Clin Psychopharmacol. 2014;34(6):728-35.
124. Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011;364(9):842-51.
125. Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127(1-3):83-92.
126. Zhornitsky S, Stip E. Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic review. Schizophr Res Treat. 2012;2012:407171.
127. Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012;73(5):617-24.
128. Fleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry. 2014;205(2):135-44.
129. Potkin SG, Raoufinia A, Mallikaarjun S, et al. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole. Curr Med Res Opin. 2013;29(10):1241-51.
130. Inoue A, Miki S, Seto M, et al. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol. 1997;321(1):105-11.
131. Jordan S, Koprivica V, Dunn R, et al. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol. 2004;483(1):45-53.
132. Park SW, Phuong VT, Lee CH, et al. Effects of antipsychotic drugs on BDNF, GSK-3beta, and beta-catenin expression in rats subjected to immobilization stress. Neurosci Res. 2011;71(4):335-40.
133. Luoni A, Fumagalli F, Racagni G, et al. Repeated aripiprazole treatment regulates Bdnf, Arc and Npas4 expression under basal condition as well as after an acute swim stress in the rat brain. Pharmacol Res. 2014;80:1-8.
134. Tadokoro S, Okamura N, Sekine Y, et al. Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. Schizophr Bull. 2012;38(5):1012-20.
135. Chouinard G, Jones BD, Annable L. Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry. 1978;135(11):1409-10.
136. Fallon P, Dursun SM. A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis. J Psychopharmacol. 2011;25(6):755-62.
137. Seeman P, Schwarz J, Chen JF, et al. Psychosis pathways converge via D2high dopamine receptors. Synapse. 2006;60(4):319-46.
138. Seeman MV, Seeman P. Is schizophrenia a dopamine supersensitivity psychotic reaction? Prog Neuropsychopharmacol Biol Psychiatry. 2014;48:155-60.
139. Fallon P, Dursun S, Deakin B. Drug-induced supersensitivity psychosis revisited: characteristics of relapse in treatment-compliant patients. Ther Adv Psychopharmacol. 2012;2(1):13-22.
140. Feltenstein MW, Altar CA, See RE. Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse. Biol Psychiatry. 2007;61(5):582-90.
141. Thomsen M, Fink-Jensen A, Woldbye DP, et al. Effects of acute and chronic aripiprazole treatment on choice between cocaine self-administration and food under a concurrent schedule of reinforcement in rats. Psychopharmacology (Berl). 2008;201(1):43-53.
142. Kinon BJ, Chen L, Ascher-Svanum H, et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology. 2010;35(2):581-90.
143. Sinclair D, Adams CE. Treatment resistant schizophrenia: a comprehensive survey of randomised controlled trials. BMC Psychiatry. 2014;14:253.
144. Bilic P, Jukic V, Vilibic M, et al. Treatment-resistant schizophrenia and DAT and SERT polymorphisms. Gene. 2014;543(1):125-32.
145. Demjaha A, Murray RM, McGuire PK, et al. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry. 2012;169(11):1203-10.
146. Quarantelli M, Palladino O, Prinster A, et al. Patients with poor response to antipsychotics have a more severe pattern of frontal atrophy: a voxel-based morphometry study of treatment resistance in schizophrenia. Biomed Res Int. 2014;2014:325052.
147. Teo C, Zai C, Borlido C, et al. Analysis of treatment-resistant schizophrenia and 384 markers from candidate genes. Pharmacogenet Genom. 2012;22(11):807-11.
148. Samaha AN, Seeman P, Stewart J, et al. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci. 2007;27(11):2979-86.
149. Gao J, Qin R, Li M. Repeated administration of aripiprazole produces a sensitization effect in the suppression of avoidance responding and phencyclidine-induced hyperlocomotion and increases D2 receptor-mediated behavioral function. J Psychopharmacol. 2015;29(4):390-400.
150. Tamminga CA. Partial dopamine agonists in the treatment of psychosis. J Neural Transm. 2002;109(3):411-20.
151. Tamminga CA, Carlsson A. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord. 2002;1(2):141-7.
152. Mottola DM, Brewster WK, Cook LL, et al. Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist. J Pharmacol Exp Ther. 1992;262(1):383-93.
153. Mottola DM, Kilts JD, Lewis MM, et al. Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther. 2002;301(3):1166-78.
154. Kilts JD, Connery HS, Arrington EG, et al. Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. J Pharmacol Exp Ther. 2002;301(3):1179-89.
155. Isacson R, Kull B, Wahlestedt C, et al. A 68930 and dihydrexidine inhibit locomotor activity and d-amphetamine-induced hyperactivity in rats: a role of inhibitory dopamine D(1/5) receptors in the prefrontal cortex? Neuroscience. 2004;124(1):33-42.
156. Ralph-Williams RJ, Lehmann-Masten V, Geyer MA. Dopamine D1 rather than D2 receptor agonists disrupt prepulse inhibition of startle in mice. Neuropsychopharmacology. 2003;28(1):108-18.
157. Mu Q, Johnson K, Morgan PS, et al. A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia. Schizophr Res. 2007;94(1-3):332-41.
158. George MS, Molnar CE, Grenesko EL, et al. A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. Schizophr Res. 2007;93(1-3):42-50.
159. Rosell DR, Zaluda LC, McClure MM, et al. Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder. Neuropsychopharmacology. 2015;40(2):446-53.
160. Zhang X, Nakata Y, Kikuchi T, et al. Interactions of 7-[3-(4-[2,3-dimethylphenyl]piperazinyl)-propoxy]-2(1H)-quinolinone binding in rat striatum: effects of lesions. Pharm Res. 1990;7(3):280-2.
161. Benkert O, Muller-Siecheneder F, Wetzel H. Dopamine agonists in schizophrenia: a review. Eur Neuropsychopharmacol. 1995;5(Suppl):43-53.
162. Newman-Tancredi A, Cussac D, Audinot V, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor. J Pharmacol Exp Ther. 2002;303(2):805-14.
163. Zorad S, Golda V, Fickova M, et al. Terguride treatment attenuated prolactin release and enhanced insulin receptor affinity and GLUT 4 content in obese spontaneously hypertensive female, but not male rats. Ann N Y Acad Sci. 2002;967:490-9.
164. Golda V, Fickova M, Pinterova L, et al. Terguride attenuates prolactin levels and ameliorates insulin sensitivity and insulin binding in obese spontaneously hypertensive rats. Physiol Res. 2001;50(2):175-82.
165. Orsini C, Koob GF, Pulvirenti L. Dopamine partial agonist reverses amphetamine withdrawal in rats. Neuropsychopharmacology. 2001;25(5):789-92.
166. Pulvirenti L, Koob GF. Dopamine receptor agonists, partial agonists and psychostimulant addiction. Trends Pharmacol Sci. 1994;15(10):374-9.
167. Pulvirenti L, Balducci C, Piercy M, et al. Characterization of the effects of the partial dopamine agonist terguride on cocaine self-administration in the rat. J Pharmacol Exp Ther. 1998;286(3):1231-8.
168. Jordan S, Johnson JL, Regardie K, et al. Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):348-56.
169. Nakai S, Hirose T, Mori T, et al. The effect of aripiprazole on prepulse inhibition of the startle response in normal and hyperdopaminergic states in rats. Int J Neurosci. 2008;118(1):39-57.
170. Jantschak F, Brosda J, Franke RT, et al. Pharmacological profile of 2-bromoterguride at human dopamine D2, porcine serotonin 5-hydroxytryptamine 2A, and alpha2C-adrenergic receptors, and its antipsychotic-like effects in rats. J Pharmacol Exp Ther. 2013;347(1):57-68.
171. Hinzen D, Hornykiewicz O, Kobinger W, et al. The dopamine autoreceptor agonist B-HT 920 stimulates denervated postsynaptic brain dopamine receptors in rodent and primate models of Parkinson's disease: a novel approach to treatment. Eur J Pharmacol. 1986;131(1):75-86.
172. Ohmori T, Koyama T, Inoue T, et al. B-HT 920, a dopamine D2 agonist, in the treatment of negative symptoms of chronic schizophrenia. Biol Psychiatry. 1993;33(10):687-93.
173. Bartoszyk GD, Harting J, Minck KO. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist. J Pharmacol Exp Ther. 1996;276(1):41-8.
174. Wetzel H, Hillert A, Grunder G, et al. Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms. Am J Psychiatry. 1994;151(10):1499-502.
175. Coward DM, Dixon AK, Urwyler S, et al. Partial dopamine-agonistic and atypical neuroleptic properties of the amino-ergolines SDZ 208-911 and SDZ 208-912. J Pharmacol Exp Ther. 1990;252(1):279-85.
176. Dyhring T, Nielsen EO, Sonesson C, et al. The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties. Eur J Pharmacol. 2010;628(1-3):19-26.
177. Tadori Y, Kitagawa H, Forbes RA, et al. Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912. Eur J Pharmacol. 2007;574(2-3):103-11.
178. Wustrow D, Belliotti T, Glase S, et al. Aminopyrimidines with high affinity for both serotonin and dopamine receptors. J Med Chem. 1998;41(5):760-71.
179. Akunne HC, Zoski KT, Davis MD, et al. PD 158771, a potential antipsychotic agent with D(2)/D(3) partial agonist and 5-HT(1A) agonist actions. I. Neurochemical effects. Neuropharmacology. 2000;39(7):1197-210.
180. Corbin AE, Meltzer LT, Ninteman FW, et al. PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT(1A) agonist actions. II. Preclinical behavioral effects. Neuropharmacology. 2000;39(7):1211-21.
181. Rugsley TA, Davis MD, Akunne HC, et al. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects. J Pharmacol Exp Ther. 1995;274(2):898-911.
182. Meltzer LT, Christoffersen CL, Corbin AE, et al. CI-1007, a dopamine partial agonist and potential antipsychotic agent. II. Neurophysiological and behavioral effects. J Pharmacol Exp Ther. 1995;274(2):912-20.
183. Feng MR, Siersma PR, Strenkoski CA, et al. Sensitive high-performance liquid chromatographic method for a dopamine receptor agonist, CI-1007, and its metabolite PD 147693 in monkey plasma. J Chromatogr B Biomed Appl. 1995;665(1):193-9.
184. Iyer RN, Davis MD, Juneau PL, et al. Brain extracellular levels of the putative antipsychotic CI-1007 and its effects on striatal and nucleus accumbens dopamine overflow in the awake rat. J Pharm Pharmacol. 1998;50(10):1147-53.
185. Sramek JJ, Eldon MA, Posvar E, et al. Initial safety, tolerability pharmacodynamics, and pharmacokinetics of CI-1007 in patients with schizophrenia. Psychopharmacol Bull. 1998;34(1):93-9.
186. Heinrich JN, Brennan J, Lai MH, et al. Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist. Eur J Pharmacol. 2006;552(1-3):36-45.
187. Klivenyi P, Vecsei L. Novel therapeutic strategies in Parkinson's disease. Eur J Clin Pharmacol. 2010;66(2):119-25.
188. Jackson MJ, Andree TH, Hansard M, et al. The dopamine D(2) receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with l-dopa. J Neural Transm. 2010;117(1):55-67.
189. Wolf W. DU-127090 Solvay/H Lundbeck. Curr Opin Investig Drugs. 2003;4(1):72-6.
190. Bardin L, Auclair A, Kleven MS, et al. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics. Behav Pharmacol. 2007;18(2):103-18.
191. Auclair AL, Galinier A, Besnard J, et al. Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats. Psychopharmacology (Berl). 2007;193(1):45-54.
192. De Santis M, Pan B, Lian J, et al. Different effects of bifeprunox, aripiprazole, and haloperidol on body weight gain, food and water intake, and locomotor activity in rats. Pharmacol Biochem Behav. 2014;124:167-73.
193. Casey DE, Sands EE, Heisterberg J, et al. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology (Berl). 2008;200(3):317-31.
194. Assie MB, Carilla-Durand E, Bardin L, et al. The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063. Eur J Pharmacol. 2008;592(1-3):160-6.
195. Citrome L. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy. Adv Ther. 2013;30(2):114-26.
196. Newman-Tancredi A, Kleven MS. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology (Berl). 2011;216(4):451-73.
197. Veselinovic T, Paulzen M, Grunder G. Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression. Expert Rev Neurother. 2013;13(11):1141-59.
198. Altinbas K, Guloksuz S, Oral ET. Clinical potential of cariprazine in the treatment of acute mania. Psychiatr Danub. 2013;25(3):207-13.
199. Pettersson F, Ponten H, Waters N, et al. Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16). J Med Chem. 2010;53(6):2510-20.
200. Natesan S, Svensson KA, Reckless GE, et al. The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat. J Pharmacol Exp Ther. 2006;318(2):810-8.
201. Rung JP, Rung E, Helgeson L, et al. Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization. J Neural Transm. 2008;115(6):899-908.
202. Ponten H, Kullingsjo J, Lagerkvist S, et al. In vivo pharmacology of the dopaminergic stabilizer pridopidine. Eur J Pharmacol. 2010;644(1-3):88-95.
203. Kara E, Lin H, Svensson K, et al. Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor. Br J Pharmacol. 2010;161(6):1343-50.
204. Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2914;350(3):589-604.
205. Maeda K, Lerdrup L, Sugino H, et al. Brexpiprazole II: antipsychotic-like profile and pro-cognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):605-14.
206. Yoshimi N, Fujita Y, Ohgi Y, et al. Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT receptors. Pharmacol Biochem Behav. 2014;124C:245-9.
207. Kane JM, Skuban A, Ouyang J, et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res. 2015;164(1-3):127-35.
208. Aihara K, Shimada J, Miwa T, et al. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. Brain Res. 2004;1003(1-2):9-17.
209. Tadori Y, Miwa T, Tottori K, et al. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur J Pharmacol. 2005;515(1-3):10-9.
210. Bruins Slot LA, De Vries L, Newman-Tancredi A, et al. Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase. Eur J Pharmacol. 2006;534(1-3):63-70.
211. Tadori Y, Forbes RA, McQuade RD, et al. Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. Eur J Pharmacol. 2008;597(1-3):27-33.
212. + channel modulation in transfected cells. Int J Neuropsychopharmacol. 2008;11(3):293-307.